Bioavailability and Pharmacokinetics

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nxera Pharma
Nxera PharmaJapan - Tokyo
1 program
1
HTL0018318Phase 11 trial
Active Trials
NCT02958696CompletedEst. Jan 2017
Teva
TevaIsrael - Petach Tikva
1 program
1
LBR-101 IVPhase 11 trial
Active Trials
NCT01991509Completed36Est. Jan 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nxera PharmaHTL0018318
TevaLBR-101 IV

Clinical Trials (2)

Total enrollment: 36 patients across 2 trials

Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules

Start: Oct 2016Est. completion: Jan 2017
Phase 1Completed
NCT01991509TevaLBR-101 IV

Safety and Bioavailability of IV and SC LBR-101

Start: Oct 2013Est. completion: Jan 201536 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space